Controversial drug approval stirs deep concerns — and hope

In September, the Food and Drug Administration approved Exondys, a treatment for muscular dystrophy based on tenuous data from just 12 patients. The cover story in & Engineering News (C&EN), the weekly newsmagazine of the American Society, explores what the decision could mean for future drugs for Duchenne and other rare diseases.

About Canada Free Press